While we cannot rule out the significant effects of other regulating factors of the RCT system, it is clear that, in the setting of obesity and hyperlipidemia, LPL inhibition-mediated alterations are associated with an increased risk of metabolic complications. Here, LPL is linked to hyperlipidemia.